Böttcher, Michael
Düngen, Hans-Dirk
Corcea, Vasile
Donath, Frank
Fuhr, Rainard
Gal, Pim
Mikus, Gerd
Trenk, Dietmar
Coenen, Martin
Pires, Philippe Vieira
Maschke, Claudia
Aliprantis, Antonios Othon
Besche, Nina
Becker, Corina http://orcid.org/0000-0003-4715-6726
Clinical trials referenced in this document:
Documents that mention this clinical trial
Vericiguat: A Randomized, Phase Ib, Placebo-Controlled, Double-Blind, QTc Interval Study in Patients with Chronic Coronary Syndromes
https://doi.org/10.1007/s40256-022-00557-2
Funding for this research was provided by:
Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).
Article History
Accepted: 10 October 2022
First Online: 12 January 2023
Declarations
:
: This study was funded by Bayer AG and Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD).
: Corina Becker and Claudia Maschke are employees of Bayer AG. Philippe Vieira Pires was previously an employee of Bayer AG at the time of the study. Michael Böttcher is a former employee of Bayer AG, and has received within the last 36 months, salary, pension, and payment for writing and reviewing vericiguat manuscripts from Bayer AG and for lectures, exercises, and awarding and supporting bachelor and master theses. Dietmar Trenk received within the last 36 months through to the foreseeable future consulting fees/payment for lectures including service on speakers’ bureaus by Amgen, AstraZeneca, Atriva, Bayer, Berlin Chemie, Bristol-Myers Squibb, Böhringer Ingelheim, Daiichi Sankyo, Ferrer, Pfizer, and Sanofi. Hans-Dirk Düngen has received institutional payment as an investigator and personal honoraria for advisory boards from Bayer. Antonios Othon Aliprantis was an employee of Merck & Co., Inc., Rahway, NJ, USA, at the time the study was conducted and held stock in the company. Rainard Fuhr is an employee of Parexel, the Clinical Research Organization that received funding from Bayer AG for the conduct of the study. Nina Besche is an employee of Chrestos Concept GmbH & Co. KG, which received funding for this analysis from Bayer AG. Martin Coenen received travel costs from Bayer AG to attend an investigator meeting related to the conduct of the study. Frank Donath, Pim Gal, Gerd Mikus, and Vasile Corcea declare no conflicts of interest.
: The study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and the ICH guideline E6: Good Clinical Practice and met all local legal and regulatory requirements. During the study, all clinical data were monitored by an independent data monitoring committee [CitationRef removed].
: All patients provided written informed consent before any study procedure was performed.
: Not applicable.
: The datasets generated and analyzed during the current study are available from the corresponding author on reasonable request.
: Not applicable.